Welcome to our dedicated page for Springworks Therapeutics SEC filings (Ticker: SWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SpringWorks Therapeutics filings document the company's completed acquisition by Merck KGaA, Darmstadt, Germany, and the resulting transition from a Nasdaq-listed public company to a wholly owned subsidiary. Material-event reports describe the merger closing, related merger-agreement disclosures, shareholder voting matters, capital-structure effects, and the status of SpringWorks common stock.
Subsequent exchange and SEC forms record the removal of SpringWorks common stock from Nasdaq listing and registration under Form 25 and the Form 15 notice terminating or suspending Exchange Act reporting obligations. Earlier filing categories include operating and financial results, governance matters, material agreements, and clinical or regulatory disclosures for its rare-disease and cancer therapy portfolio.
Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC report beneficial ownership of 4,234,033.35 shares of SpringWorks Therapeutics common stock, representing 5.6% of the class. The filing shows the positions are held with shared voting power (4,233,899.35 shares) and shared dispositive power (4,234,021.35 shares), and no sole voting or dispositive power is reported. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a joint filing agreement and identifies Goldman Sachs & Co. LLC as a subsidiary of the parent reporting entity.
Hudson Bay Capital Management LP and Sander Gerber report beneficial ownership of 3,936,857 shares of SpringWorks Therapeutics, representing 5.22% of the outstanding common stock. The reported position includes 3,529,200 shares issuable upon exercise of call options. The filings show no sole voting or dispositive power and shared voting and dispositive power of 3,936,857 shares, indicating the securities are held in the name of the fund managed by the Investment Manager.
The Schedule 13G filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The ownership percentage is calculated using an outstanding share base of 75,348,995 shares as disclosed in the company proxy.